References

The impact of cancer stem cells in colorectal cancer

10.3390/ijms25084140 · 2024 · External reference

Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN

10.1136/gutjnl-2022-327736 · 2023 · External reference

An examination of colorectal cancer burden by socioeconomic status: evidence from GLOBOCAN 2018

10.1007/s13167-019-00185-y · 2020 · External reference

Cancer of colon, rectum and anus: the rising burden of disease worldwide from 1990 to 2019

10.1093/pubmed/fdad197 · 2024 · External reference

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge

10.1093/annonc/mdy509 · 2019 · External reference

Intratumor CMS heterogeneity impacts patient prognosis in localized colon cancer

10.1158/1078-0432.ccr-21-0529 · 2021 · External reference

Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer

10.1038/s41419-023-05806-z · 2023 · External reference

The role of p53 dysfunction in colorectal cancer and its implication for therapy

10.3390/cancers13102296 · 2021 · External reference

The role of KRAS mutations in colorectal cancer: biological insights, clinical implications, and future therapeutic perspectives

10.3390/cancers17030428 · 2025 · External reference

Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: updates and beyond

10.3748/wjg.v29.i9.1395 · 2023 · External reference

Comprehensive review of targeted therapy for colorectal cancer

10.1038/s41392-020-0116-z · 2020 · External reference

Long-term resistance to 5-fluorouracil promotes epithelial-mesenchymal transition, apoptosis evasion, autophagy, and reduced proliferation rate in colon cancer cells

10.1016/j.ejphar.2022.175253 · 2022 · External reference

Association of the epithelial-mesenchymal transition (EMT) with cisplatin resistance

10.3390/ijms21114002 · 2020 · External reference

The effect and mechanism of erianin on the reversal of oxaliplatin resistance in human colon cancer cells

10.1002/cbin.11684 · 2021 · External reference

Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling

10.1186/s40425-019-0701-2 · 2019 · External reference

Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κb/STAT3-regulated proteins

10.1038/s41419-020-2675-x · 2020 · External reference

Pharmacological NF-κb inhibition decreases cisplatin chemoresistance in muscle-invasive bladder cancer and reduces cisplatin-induced toxicities

10.1002/1878-0261.13504 · 2023 · External reference

STAT3 regulates 5-Fu resistance in human colorectal cancer cells by promoting Mcl-1-dependent cytoprotective autophagy

10.1111/cas.15761 · 2023 · External reference

NF-κb in biology and targeted therapy: new insights and translational implications

10.1038/s41392-024-01757-9 · 2024 · External reference

Targeting STAT3 in cancer immunotherapy

10.1186/s12943-020-01258-7 · 2020 · External reference

NF-κb in inflammation and cancer

10.1038/s41423-025-01310-w · 2025 · External reference

Modulating multidrug resistance to drug-based antitumor therapies through NF-κb signaling pathway: mechanisms and perspectives

10.1080/14728222.2023.2225767 · 2023 · External reference

The bright side of Curcumin: a narrative review of its therapeutic potential in cancer management

10.3390/cancers16142580 · 2024 · External reference

A review of curcumin and its derivatives as anticancer agents

10.3390/ijms20051033 · 2019 · External reference

Antitumoral activities of curcumin and recent advances to ImProve its oral bioavailability

10.3390/biomedicines9101476 · 2021 · External reference

Developments in the anticancer activity of structurally modified curcumin: an up-to-date review

10.1016/j.ejmech.2019.04.058 · 2019 · External reference

The potency of heterocyclic curcumin analogues: an evidence-based review

10.1016/j.phrs.2021.105489 · 2021 · External reference

Molecular mechanisms of curcumin and its analogs in colon cancer prevention and treatment

10.1016/j.lfs.2019.117032 · 2019 · External reference

Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery

10.1186/s13046-024-02949-5 · 2024 · External reference

Targeted therapies of curcumin focus on its therapeutic benefits in cancers and human health: molecular signaling pathway-based approaches and future perspectives

10.1016/j.biopha.2023.116034 · 2024 · External reference

Systematic elucidation of the mechanism of action of Curcumin against colorectal cancer via network pharmacology approach

2021 · External reference

Curcumin delivery systems: how far from clinical application in tumor therapy?

2024 · External reference

Unresolved reference

2020 · External reference

Curcumin’s potential as A drug delivery method and anticancer treatment

10.37021/ijper.v5i2.04 · 2023 · External reference

Curcumin and its anti-colorectal cancer potential: from mechanisms of action to autophagy

10.1002/ptr.8220 · 2024 · External reference

The inflammatory pathogenesis of colorectal cancer

10.1038/s41577-021-00534-x · 2021 · External reference

TNF-α synergises with IFN-γ to induce caspase-8-JAK1/2-STAT1-dependent death of intestinal epithelial cells

10.1038/s41419-021-04151-3 · 2021 · External reference

STAT3 as a newly emerging target in colorectal cancer therapy: tumorigenesis, therapy response, and pharmacological/nanoplatform strategies

10.1016/j.envres.2023.116458 · 2023 · External reference

Data from cytokine Induction of Tumor Necrosis factor receptor 2 Is mediated by STAT3 in colon

2023 · External reference

NF-κb signaling in inflammation and cancer

10.1002/mco2.104 · 2021 · External reference

Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

10.1038/s41392-021-00670-9 · 2021 · External reference

Aspirin suppresses chemoresistance and enhances antitumor activity of 5-fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-\\u03baB activation

10.1038/s41598-019-53276-1 · 2019 · External reference

Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models

10.1002/1878-0261.13595 · 2024 · External reference

IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming

10.1038/s41389-021-00349-4 · 2021 · External reference

IL-6 regulates autophagy and chemotherapy resistance by promoting BECN1 phosphorylation

10.1038/s41467-021-23923-1 · 2021 · External reference

STAT3 and the STAT3-regulated inhibitor of apoptosis protein survivin as potential therapeutic targets in colorectal cancer (Review)

10.3892/br.2024.1863 · 2024 · External reference

Progress in understanding the IL-6/STAT3 pathway in colorectal cancer

10.2147/ott.s278013 · 2020 · External reference

Overcoming acquired drug resistance to cancer therapies through targeted STAT3 inhibition

10.3390/ijms24054722 · 2023 · External reference

Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: an updated review (from 2022 to 2024)

10.1016/j.cclet.2024.110447 · 2025 · External reference

Interleukins in cancer: from biology to therapy

10.1038/s41568-021-00363-z · 2021 · External reference

Curcumin nicotinate selectively induces cancer cell apoptosis and cycle arrest through a P53-mediated mechanism

10.3390/molecules24224179 · 2019 · External reference

Rafoxanide negatively modulates STAT3 and NF-κb activity and inflammation-associated colon tumorigenesis

10.1111/cas.16317 · 2024 · External reference

Unresolved reference

2023 · External reference

Anti-obesity drug orlistat alleviates western-diet-driven colitis-associated colon cancer via inhibition of STAT3 and NF-κb-mediated signaling

10.3390/cells10082060 · 2021 · External reference

Important chemical structural features of curcumin and its derivatives: how do they influence their anticancer activity?

2020 · External reference

Curcumin induces apoptosis in human hepatocellular carcinoma cells by decreasing the expression of STAT3/VEGF/HIF-1α signaling

2023 · External reference

Curcumin in prostate cancer: a systematic review of molecular mechanisms and nanoformulated therapeutic strategies

10.1186/s12885-025-15152-2 · 2025 · External reference

Curcumin activates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress colorectal cancer metastasis

10.1038/s41418-023-01178-1 · 2023 · External reference

Natural products as chemo-radiation therapy sensitizers in cancers

10.1016/j.biopha.2022.113610 · 2022 · External reference

A review of different approaches for improving curcumin bioavailability

10.22270/jddt.v13i12.6267 · 2023 · External reference

Assessment of enhancing curcumin’s solubility versus uptake on its anti-cancer efficacy

10.1016/j.colsurfb.2024.114090 · 2024 · External reference

Review of Curcumin and its different formulations: pharmacokinetics, pharmacodynamics and pharmacokinetic-pharmacodynamic interactions

10.21926/obm.icm.2204057 · 2022 · External reference

Enhancing the bioavailability and bioactivity of curcumin for disease prevention and treatment

10.3390/antiox13030331 · 2024 · External reference

Enhancing therapeutic impact of curcumins, through development of monocarbonyl analogues of curcumin for improved bioavailability and activity in healthcare

10.2174/0122103155307922241022143752 · 2026 · External reference

Curcumin-based nanoparticles: advancements and challenges in tumor therapy

10.3390/pharmaceutics17010114 · 2025 · External reference

Enhancing therapeutic efficacy of Curcumin: advances in delivery systems and clinical applications

10.3390/gels9080596 · 2023 · External reference

Curcumin nanoformulations for colorectal cancer: a review

10.3389/fphar.2019.00152 · 2019 · External reference

Herbal approach for treatment of cancer using curcumin as an anticancer agent: a review on novel drug delivery systems

10.1016/j.molliq.2023.123037 · 2023 · External reference

Trends in advanced oral drug delivery systems for curcumin: a systematic review

10.1016/j.jconrel.2022.05.048 · 2022 · External reference

Utility of intravenous curcumin nanodelivery systems for improving in vivo pharmacokinetics and anticancer pharmacodynamics

10.1021/acs.molpharmaceut.2c00455 · 2022 · External reference

Gut microbiota in phytopharmacology: a comprehensive overview of concepts, reciprocal interactions, biotransformations and mode of actions

10.1016/j.phrs.2019.104367 · 2019 · External reference

Curcumin β-D-glucuronide exhibits anti-tumor effects on oxaliplatin-resistant colon cancer with less toxicity in vivo

10.1111/cas.14383 · 2020 · External reference

Recent advances of analogues of curcumin for treatment of cancer

10.1016/j.ejmech.2019.07.034 · 2019 · External reference

Preparation and anti-colon cancer effect of a novel curcumin analogue (CA8): in vivo and in vitro evaluation

10.3389/fphar.2024.1464626 · 2024 · External reference

Tumour-suppressive effects of curcumin analogs CCA-1.1 and pentagamavunone-1 in colon cancer: in vivo and in vitro studies

10.4103/japtr.japtr_315_23 · 2023 · External reference

Preparation and cytotoxic evaluation of PGV-1 derivative, CCA-1.1, as a new curcumin analog with improved-physicochemical and pharmacological properties

10.34172/apb.2022.063 · 2022 · External reference

An old spice with new tricks: curcumin targets adenoma and colorectal cancer stem-like cells associated with poor survival outcomes

10.1016/j.canlet.2025.217885 · 2025 · External reference

The curcumin analogue, MS13 (1,5-Bis(4-hydroxy-3- methoxyphenyl)-1,4-pentadiene-3-one), inhibits cell proliferation and induces apoptosis in primary and metastatic Human colon cancer cells

10.3390/molecules25173798 · 2020 · External reference

Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-wnt signal pathway to inhibit the EMT progress

10.1016/j.biopha.2020.110381 · 2020 · External reference

AI-guided design of leucopelargonidin-derived ligands targeting glucokinase regulatory protein: quantum descriptors, binding dynamics, and network pharmacology

10.1016/j.chphi.2026.101102 · 2026 · External reference

Proteomic analysis of the chemosensitizing effect of curcumin on CRC cells treated with 5-FU

10.3389/fmed.2022.1032256 · 2022 · External reference

Curcumin against gastrointestinal cancer: a review of the pharmacological mechanisms underlying its antitumor activity

10.3389/fphar.2022.990475 · 2022 · External reference

Curcumin in colorectal cancer: mechanistic insights, pharmacological limitations, and translational perspectives

2025 · External reference

Cancer stem cells: advances in knowledge and implications for cancer therapy

10.1038/s41392-024-01851-y · 2024 · External reference

Low curcumin concentration enhances the anticancer effect of 5-fluorouracil against colorectal cancer

10.1016/j.phymed.2021.153547 · 2021 · External reference

Curcumin and derivatives in nanoformulations with therapeutic potential on colorectal cancer

2022 · External reference

Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase IIa trial

10.1093/jn/nxz029 · 2019 · External reference

Synthesis and biological evaluations of monocarbonyl analogs of curcumin with improved stability and pharmacological properties

10.2147/dddt.s244865 · 2020 · External reference

The therapeutic potential of curcumin: a review of clinical trials

10.1016/j.ejmech.2018.12.016 · 2019 · External reference

Smart polymer-based delivery systems for curcumin in colon cancer therapy: a review

10.1002/ptr.8394 · 2025 · External reference

Curcumin loaded eudragit S100/PLGA nanoparticles in treatment of colon cancer: formulation, optimization, and in-vitro cytotoxicity study

10.5530/ijper.55.2s.114 · 2021 · External reference

Folate-modified curcumin-loaded nanoparticles for overcoming delivery challenges in cancer treatment: a narrative review

10.2174/0113892010299290240531101441 · 2025 · External reference

Fabrication of targeted and pH responsive lysozyme-hyaluronan nanoparticles for 5-fluorouracil and curcumin co-delivery in colorectal cancer therapy

10.1016/j.ijbiomac.2023.127836 · 2024 · External reference

Co-administration of curcumin with other phytochemicals improves anticancer activity by regulating multiple molecular targets

10.1002/ptr.7794 · 2023 · External reference

Curcuma as an adjuvant in colorectal cancer treatment

10.1016/j.lfs.2021.120043 · 2021 · External reference

Is curcumin at the threshold of therapeutic effectiveness on patients with colon cancer?-A systematic review

2021 · External reference

Curcumin and colorectal cancer: from basic to clinical evidences

10.3390/ijms21072364 · 2020 · External reference

Review on regulation of herbal products used as a medicine across the globe: a case study on turmeric - golden medicine

10.13005/bpj/2458 · 2022 · External reference

Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway

10.2147/ott.s199601 · 2019 · External reference

Curcumin-loaded porous particles functionalized with pH-responsive cell-penetrating peptide for colorectal cancer targeted drug delivery

10.1039/d3ra06270h · 2023 · External reference

Curcumin formulations for better bioavailability: what we learned from clinical trials thus far?

10.1021/acsomega.2c07326 · 2023 · External reference